We are excited to join healthcare professionals and patients from around the world to learn more about the cutting-edge research and advancements in treatments at the American Diabetes Association (ADA) 84th Scientific Sessions, June 21-24, 2024, in Orlando, Florida. We will be presenting new preclinical data for our investigational product REJUVA® on Sunday, June 23rd, from 1:30-1:45 p.m. ET, in the Valencia Ballroom. This abstract was recognized as noteworthy and selected by the Scientific Sessions Meeting Planning Committee as one of eight President’s Select Abstracts. #ADA2024 #ADAScientificSessions #Fractyl #obesity #type2diabetes #T2D #biotech *Rejuva is in preclinical development and has yet to be assessed by regulatory agencies.
Fractyl Health’s Post
More Relevant Posts
-
Advancements in cellular and molecular biotechnology have led to the introduction of 26 ATMPs in the EU market, showcasing their transformative potential across various medical areas. 🧬 🌎 Recent safety signals are reshaping patient access to #ATMPs, marking a pivotal moment in medical innovation and regulation. Click the link to explore the 𝐜𝐫𝐢𝐭𝐢𝐜𝐚𝐥 𝐜𝐨𝐧𝐬𝐢𝐝𝐞𝐫𝐚𝐭𝐢𝐨𝐧𝐬 posed by these signals in our latest blog written by Market Access Analyst Manahill Baig 👉 https://lnkd.in/grZXVjYk #marketaccess #patientaccess #genetherapy #advancedtherapies #medicalinnovation #pharma #healthcare
To view or add a comment, sign in
-
🎬 Resolian Video Series Finale: Chapter 9 🌟 The final of our video series featuring our CEO Patrick Bennett with Chris Conner from Life Science Marketing Radio. 🔍 “Unveiling the Heartbeat - Bringing Benefits to Patients!” In this final instalment, we explore Resolian's impact on patients' experiences in clinical trials. Unlike central labs or clinical diagnostics, bioanalysis often involves unique methods, limiting optimal locations for sample analysis. Resolian's global network, with laboratories in multiple geographies, provides our pharma clients the leverage to strategically choose where they run analyses in alignment with their clinical trials. This not only expands the options for clients but, more importantly, broadens the reach of clinical trials, benefiting a larger population of patients around the globe. Missed a chapter? Watch all the chapters on our YouTube channel: https://lnkd.in/e7B9SGCG #Resolian #VideoSeries #CompanyCulture #LabInnovation #WatchNow #Bioanalytics #bioanalyticalservices #AnalyticalSciences #ContractResearchOrganization #CRO #biotech #lifescience #pharma #drugdevelopment 🎥
To view or add a comment, sign in
-
Miscalculations of critical PK values can cause cascading problems that impact clinical trial outcomes, drug development timelines, and costs. By leveraging advanced multi-organ human in vitro models, such as our human PhysioMimix® Gut/Liver-on-a-chip, we can unlock a deeper understanding of how our bodies Absorb, Distribute and Metabolize drugs, and their potential bioavailability to mitigate risk before clinical trials. 👉Read the full article for deeper insights: https://bit.ly/3YzVRb1 • Change the risk calculus by broadening the ADME toolbox • Importance of a varied toolbox, combing in vitro, in vivo & in silico • Why identifying human intestinal first-pass metabolism is crucial? • Is the current ADME toolbox fit for advanced drug modalities? #OrganOnAChip #ADME #DrugDevelopment #Bioavailability
To view or add a comment, sign in
-
Advisory Partner at Moss Adams supporting Life Sciences and Technology Companies Throughout the West & Beyond
Macroeconomic forces can only carry the biotech sector so far—innovative new drugs, and the study data that supports them, are what sustains investors’ attention. Here are 10 imminent clinical trial readouts to watch as we open up the New Year.
To view or add a comment, sign in
-
#Orphandiseases are often chronic or life-threatening, yet most don’t have an effective treatment. Research for these is incentivised by #orphandrugdesignation which requires robust evidence. Read our case study to learn how we have supported this at http://bit.ly/3kdfWh9. -Orphan drug designation for a new investigative treatment of idiopathic pulmonary fibrosis (IPF) was granted by both the FDA and EMA. “The Company was “very pleased” to receive orphan drug designation (ODD) in both the US and EU. The EMA cited clinically relevant biomarker data as a justification for the ODD designation. The data presented provided evidence of a “clinically relevant advantage” over existing treatments, offering the potential to “address a significant unmet medical need.” Biotech CEO #rarediseases #biotech #lifesciences #IPF
To view or add a comment, sign in
-
🧬 In a groundbreaking stride for biopharmaceuticals, we're decoding the enigmatic world of Yeast Signal Peptides! 🧫 Discover the transformative impact these peptides could have on healthcare. #YeastSignalPeptideDetection is more than a buzzword; it's the future unwrapped. 🔍 Dive into the heart of bioscience innovation with our latest exploration: 'Cracking the Code: Unraveling Yeast Signal Peptides.' From boosting protein production to pioneering new therapies, the implications are as vast as they are exciting. 🚀Unlock the full story at https://bit.ly/3X2QdgP and be at the forefront of this thrilling scientific narrative. 🌐#Biopharmaceuticals #HealthcareInnovation #ScienceBreakthroughs
To view or add a comment, sign in
-
Macroeconomic forces can only carry the biotech sector so far—innovative new drugs, and the study data that supports them, are what sustains investors’ attention. Here are 10 imminent clinical trial readouts to watch as we open up the New Year.
10 clinical trials to watch in the first half of 2024
biopharmadive.com
To view or add a comment, sign in
-
Macroeconomic forces can only carry the biotech sector so far—innovative new drugs, and the study data that supports them, are what sustains investors’ attention. Here are 10 imminent clinical trial readouts to watch as we open up the New Year.
10 clinical trials to watch in the first half of 2024
biopharmadive.com
To view or add a comment, sign in
-
Macroeconomic forces can only carry the biotech sector so far—innovative new drugs, and the study data that supports them, are what sustains investors’ attention. Here are 10 imminent clinical trial readouts to watch as we open up the New Year.
10 clinical trials to watch in the first half of 2024
biopharmadive.com
To view or add a comment, sign in
-
Accounting | Auditing | Advisory | Consulting | Education | Higher Ed | Not-for-Profit | FQHC | Health Care | Life Science | Public Sector | Federal Grants Contracts | Uniform Guidance | DEIBJ | Racial Equity | I&D | ESG
Macroeconomic forces can only carry the biotech sector so far—innovative new drugs, and the study data that supports them, are what sustains investors’ attention. Here are 10 imminent clinical trial readouts to watch as we open up the New Year.
10 clinical trials to watch in the first half of 2024
biopharmadive.com
To view or add a comment, sign in
7,480 followers
Global Strategic Partnerships Manager - driving medical education growth
3moSee you in Orlando on the weekend! 😎